Blood Advances

Blood Advances
Prospective KIR Genotype Evaluation of Hematopoietic Cell Donors is Feasible With Potential to Benefit Patients With AML

This study demonstrates that donor KIR typing is feasible, and prioritization of donors with certain KIR3DL1 genotypes may confer a protection from relapse after HCT in patients with AML.

Blood Advances
Efficacy and Safety of Copanlisib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Enhanced efficacy outcomes can result from prolonged duration of copanlisib therapy in patients with relapsed/refractory MZL.

Blood Advances
Active Surveillance of Primary Extranodal Marginal Zone Lymphoma of Bronchus-Associated Lymphoid Tissue

This retrospective study shows that BALT lymphoma can often be managed expectantly and not require therapy for many years.

Blood Advances
Durable Ibrutinib Responses in Relapsed/Refractory Marginal Zone Lymphoma: Long-Term Follow-Up and Biomarker Analysis

Study investigators find that with extended follow-up, ibrutinib demonstrates durable clinical benefit in patients with relapsed/refractory MZL.

Blood Advances
Functional Characterization of PD1+TIM3+ Tumor-Infiltrating T Cells in DLBCL and Effects of PD1 or TIM3 Blockade

Activated B cell–like DLBCL shows increased levels of PD1+TIM3+ TILs with impaired functions.

Blood Advances
Outcomes of Older Patients With Follicular Lymphoma

Older patients with FL have similar early disease outcomes to younger patients. Age alone should not disqualify older FL patients from standard treatments or RCTs.

Blood Advances
Rheumatologic Diseases Impact the Risk of Progression of MGUS to Overt Multiple Myeloma

The risk of progression is doubled for MGUS patients with non-Ab–mediated RDs compared with those without concomitant RDs.

Blood Advances
Misdiagnosed Thrombocytopenia in Children and Adolescents: Analysis of the Pediatric and Adult Registry on Chronic ITP

Misdiagnosed primary ITP in children is rare in the international prospective Pediatric and Adult Registry on Chronic ITP.

Blood Advances
Long-term Outcomes of R-CEOP Show Curative Potential in Patients With DLBCL and a Contraindication to Anthracyclines

The R-CEOP regimen is a valid alternative to R-CHOP for patients with de novo DLBCL and an absolute contraindication to anthracyclines.

Blood Advances
Relationship of Donor Age and Relationship to Outcomes of Haploidentical Transplantation With Posttransplant Cyclophosphamide

This study seeks to identify factors to optimize the choice of haplo donors when using posttransplantation cyclophosphamide GVHD prophylaxis.

Blood Advances
Subscribe to Blood Advances

source list reference